VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
March 4, 2013 2:18 PM ESTArena Pharmaceuticals, Inc. (Nasdaq: ARNA) is active today following a conference call earlier following fourth-quarter 2012 results and to also provide an update on Belviq.
Needham and Company analyst Alan Carr is out with a few comments and observations following the call.
Arena said it was waiting for a final decision on Belviq... More
VIVUS (VVUS) Schedules Three Presentations for March 2013
March 4, 2013 6:46 AM ESTVIVUS, Inc. (Nasdaq: VVUS) today announced that management will present an overview of the company at three investment conferences during the month of March 2013.
The conference presentation schedule is as follows:Cowen and Company 33rd Annual Health Care Conference
March 5, 2013, 8:00am... More
VIVUS, Inc. (VVUS) Misses Q4 Views on Heftier Qsymia Costs; Analysts Comment
February 26, 2013 9:23 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is lower in early trading Tuesday following fourth-quarter results issued after markets closed Monday.
The company reported a loss of 56 cents per share on revs of $1.97 million. The Street was looking for a loss of 44 cents per share and revs of $3.09 million.
For more color on the results, click here.
Analysts are out with a few... More
Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
February 25, 2013 1:15 PM ESTArena Pharmaceutical (Nasdaq: ARNA) is positive on the session following earlier disclosure of the price for a 60-day supply of... More
